Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 8, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: May 4, 2006
- Previous Holding: 17,432,485 ADRs
- New Holding: 17,312,621 ADRs
- Transaction Price: $55.45
- Net Change: Decrease of 119,864 ADRs
This change resulted from a movement in the fund. The Plan is a discretionary fund for current and former employees. Directors Dr. J P Garnier and Dr. T Yamada are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding director and connected person interests.
Key Facts for Investor Verification
- Verify the impact of the 119,864 ADR reduction on the total share count of the US Retirement Savings Plan.
- Confirm the specific nature of the "movement in the fund" that triggered the share reduction on May 4, 2006.
- Review the broader context of the Plan's holdings to assess the significance of this change relative to total employee ownership.
- Note that this filing does not contain operational or financial performance data for the period.